Core Viewpoint - Jinshi Yao (300434) has responded to investor inquiries on September 22, indicating that the company has disclosed the number of shareholders in its periodic reports, encouraging investors to pay attention to this information [1] Group 1 - The company has engaged with investors through an interactive platform [1] - The company emphasizes the importance of its periodic reports for shareholder information [1]

证券日报网讯金石亚药（300434）9月17日在互动平台回答投资者提问时表示，公司不涉及生产PBO材 料，目前正在进行PBO材料表面金属化处理的真空镀膜设备的研发工作。在研项目如果有实质性进展， 公司将会严格按照相关要求履行信息披露义务。 ...

2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议的召开情况 1、会议召开的时间 证券代码：300434 证券简称：金石亚药 公告编号：2025-038 四川金石亚洲医药股份有限公司 2025 年第一次临时股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形； （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 9 月 12 日的交易时间，即 9:15-9:25，9:30-11:30 和 13:00-15:00；通 过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 9 月 12 日 9:15-15:00 的任意时间。 2、现场会议召开地点：杭州市滨江区江南大道 4760 号亚科中心公司会议室 3、会议召开方式：本次股东会采取现场投票和网络投票相结合的方式 出席本次股东会现场会议和参加网络投票的股东及股东代理人共 132 人，代 表公司有表决权的股份数 200,547,262 股，占公司有表决权股份总数的 49.9192%。 4、会议 ...

金石亚药 2025 年第一次临时股东会法律意见书 北京天驰君泰（杭州）律师事务所 北京天驰君泰（杭州）律师事务所 关 于 四川金石亚洲医药股份有限公司 2025 年第一次临时股东会 法律意见书 北京天驰君泰（杭州）律师事务所 BEIJING TIANTAI LAW FIRM（HangZhou） 地址：浙江省杭州市滨江区西兴街道中海发展大厦 T3 六层 电话：86+0571-86681860 邮编：310052 二〇二五年九月 金石亚药 2025 年第一次临时股东会法律意见书 北京天驰君泰（杭州）律师事务所 北京天驰君泰（杭州）律师事务所 在本法律意见书中，本所律师根据本法律意见书出具日以前发生或存在的事 实及有关法律、行政法规、规范性文件及《公司章程》的规定，仅就本次股东会 召集和召开程序的合法有效性、出席会议人员资格和会议召集人资格的合法有效 性、会议表决程序和表决结果的合法有效性发表意见，而不对本次股东会所审议 的议案内容和该等议案中所表述的事实或数据的真实性和准确性发表意见。 本法律意见书仅供公司为本次股东会之目的而使用，不得被任何人用于其他 任何目的。本所同意，公司可以将本法律意见书作为公司本次股东会 ...

Core Insights - The company Jinshi Yiyao (300434) reported a total revenue of 492 million yuan for the first half of 2025, a decrease of 5.8% year-on-year, while the net profit attributable to shareholders increased by 67.71% to 65.74 million yuan [1] - The second quarter of 2025 showed a revenue of 200 million yuan, reflecting a year-on-year increase of 25.77%, and a net profit of 2.89 million yuan, up 105.72% year-on-year [1] - The company's profitability improved, with a slight increase in gross margin and a significant rise in net margin [1] Financial Performance - Total revenue for 2025 was 492 million yuan, down from 522 million yuan in 2024, marking a decline of 5.8% [1] - Net profit attributable to shareholders rose to 65.74 million yuan from 39.20 million yuan, an increase of 67.71% [1] - The gross margin was 56.89%, a slight increase of 0.05% year-on-year, while the net margin improved significantly to 13.09%, up 79.86% [1] - Total expenses (selling, administrative, and financial) amounted to 172 million yuan, accounting for 34.95% of revenue, down 8.62% year-on-year [1] Cash Flow and Assets - Cash and cash equivalents increased to 408 million yuan, a rise of 55.30% from 263 million yuan [1] - Accounts receivable rose to 107 million yuan, an increase of 18.44% from 90.76 million yuan [1] - The company’s interest-bearing debt surged to 133 million yuan, a significant increase of 403.44% from 26.37 million yuan [1] Earnings and Shareholder Metrics - Earnings per share (EPS) increased to 0.16 yuan from 0.10 yuan, reflecting a growth of 67.73% [1] - The net asset value per share rose to 6.19 yuan, up 3.78% from 5.96 yuan [1] - Operating cash flow per share improved significantly to 0.37 yuan from -0.22 yuan, a rise of 265.86% [1] Business Evaluation - The company's return on invested capital (ROIC) was 3.32%, indicating weak capital returns [3] - The historical median ROIC since listing is 6.74%, with a notably poor performance in 2020, where ROIC was -28.39% [3] - The company's business model relies heavily on marketing, necessitating further investigation into the underlying drivers of this approach [3] - The accounts receivable situation is concerning, with accounts receivable to profit ratio reaching 117.15% [3]

Group 1 - The core viewpoint of the article is that Jinshi Yao (300434.SZ) reported a decrease in revenue for the first half of 2025, while net profit showed significant growth [1] Group 2 - The company's operating revenue for the first half of 2025 was 492 million yuan, representing a year-on-year decrease of 5.80% [1] - The net profit attributable to shareholders of the listed company was 65.74 million yuan, reflecting a year-on-year increase of 67.71% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 55.72 million yuan, which is a year-on-year increase of 50.45% [1] - The basic earnings per share were 0.1637 yuan [1]

Core Viewpoint - Jinshi Yao (300434.SZ) reported a decrease in operating revenue for the first half of 2025, while net profit showed significant growth [1] Financial Performance - The company's operating revenue for the first half of 2025 was 492 million yuan, representing a year-on-year decrease of 5.80% [1] - Net profit attributable to shareholders was 65.74 million yuan, reflecting a year-on-year increase of 67.71% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 55.72 million yuan, which is a year-on-year increase of 50.45% [1] - Basic earnings per share were 0.1637 yuan [1]

Core Viewpoint - Jinshiyao Pharmaceutical (300434) announced the election of Yang Liu as the employee representative director of the fifth board of directors during the employee representative meeting held on August 25, 2025 [1] Group 1 - The employee representative meeting took place on August 25, 2025 [1] - Yang Liu was elected as the employee representative director [1]

第三条 公司应当严格按照法律、行政法规、本规则及《公司章程》的相关 规定召开股东会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当 勤勉尽责，确保股东会正常召开和依法行使职权。 四川金石亚洲医药股份有限公司 股东会议事规则 （尚需经公司 2025 年第一次临时股东会审议通过） 第一章 总 则 第一条 为完善四川金石亚洲医药股份有限公司（下称 "公司"） 法人治理 结构，明确股东会的职责权限，确保公司股东会依法规范地召开，提高股东会议 事效率，保证公司决策行为的民主、科学，根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上 市公司股东会规则》《深圳证券交易所创业板股票上市规则》（以下简称"《上市 规则》"）等法律法规、规范性文件及《四川金石亚洲医药股份有限公司章程》（以 下简称"《公司章程》"）的有关规定，结合公司实际情况，制定本规则。 第二条 公司股东会的召集、提案、通知、召开等事项适用本规则。 第四条 股东会应当在《公司法》和《公司章程》规定的范围内行使职权。 第五条 股东会分为年度股东会和临时股 ...

四川金石亚洲医药股份有限公司 董事会审计委员会工作细则 第一章 总 则 第一条 为强化董事会决策功能，做到事前审计、专业审计，确保董事会对 经理层的有效监督，完善四川金石亚洲医药股份有限公司（以下简称"公司"） 内部控制，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上 市公司治理准则》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律法规、规范性 文件及《四川金石亚洲医药股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，公司设立董事会审计委员会，并制定本工作细则。 第二条 董事会审计委员会是董事会依据相应法律法规设立的专门工作机构， 主要负责公司财务信息及披露、监督及评估内外部审计工作和内部控制，对董事 会负责，审计委员会的提案提交董事会审议决定。 第二章 人员组成 第三条 审计委员会成员由三名董事组成，为不在公司担任高级管理人员的 董事，其中独立董事两名，至少有一名独立董事为会计专业人士。董事会成员中 的职工代表可以成为审计委员会成员。 本条所称"会计专业人士"，应当具备丰富的会计专业知识和经验，并至少 符合下列条件 ...